Research programme: aminoglycoside antibacterials - Biolex
Alternative Names: Aminoglycoside (Transport Molecule) research programme - Biolex; Pseudomonal infections therapy research programme - BiolexLatest Information Update: 01 Oct 2012
Price :
$50 *
At a glance
- Originator Biolex
- Class Aminoglycosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 03 Jul 2012 Biolex files for Chapter 7 bankruptcy in the US Bankruptcy Court for the Middle District of North Carolina
- 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
- 11 Mar 1999 Preclinical development for Cystic fibrosis-associated respiratory tract infections in USA (Parenteral)